The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Alprazolam (N05BA12)

Cinacalcet (H05BX01)

Diclofenac (D11AX18) exclusively topical dosage forms

Dronedaron (C01BD07)

Dutasterid & Tamsulosin (G04CA52)

Erlotinib (L01EB02)

Erythropoietin (B03XA01)

Fulvestrant (L02BA03)

Ibuprofen (M01AE01; M02AA13)

levodopa in combination with benserazide (N04BA11) exclusively for the treatment of restless legs syndrome

Metoclopramide (A03FA01)

Tiotropium (R03BB04) other than hard capsules with inhalation powder

Valproic acid (N03AG01)

Zolmitriptan (N02CC03)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.06.2023. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.06.2023. Based on this, the contract term is a maximum of 24 months.